Premium
SNAP25 reflects amyloid‐ and tau‐related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic disfunction in the Alzheimer’s disease spectrum
Author(s) -
Benedet Andréa Lessa,
Ashton Nicholas J.,
Pascoal Tharick A.,
Brinkmalm Ann,
Nilsson Johanna,
Kvartsberg Hlin,
Mathotaarachchi Sulantha,
Savard Mélissa,
Therriault Joseph,
Tissot Cécile,
Chamoun Mira,
Zetterberg Henrik,
Blennow Kaj,
RosaNeto Pedro
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.046358
Subject(s) - neurogranin , cerebrospinal fluid , biomarker , dementia , pathology , medicine , grey matter , voxel , neuroscience , voxel based morphometry , white matter , psychology , oncology , disease , magnetic resonance imaging , biology , radiology , biochemistry , protein kinase c , enzyme
Background It is widely accepted that synaptic dysfunction is an early core feature of Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) biomarkers of synaptic damage have already been associated with amyloid and tau pathologies as well as with cognitive decline in the AD spectrum. However, to the best of our knowledge, no study has yet shown the relationship between CSF biomarkers and PET biomarkers at the voxel‐level for these pathologies. Thus, we aim to investigate the association between several biomarkers of synaptic damage and amyloid and tau, in the AD spectrum, using data from the Translational Biomarkers of Aging and Dementia (TRIAD) cohort. Method 163 participants (23 young controls, 77 normal controls, 37 mild cognitive impairment, 22 AD and 9 FTD) were evaluated with cross‐sectional CSF biomarkers, [ 18 F]MK6240 and [ 18 F]AZD4694 PET as well as white(WM) and grey matter(GM) MRI voxel‐based morphometry (VBM). For PET, SUVRs were determined using the cerebellar cortex as reference tissue. The CSF biomarkers were quantified by in‐house immunoassays for neurogranin and neuromodulin (GAP‐43), whereas SNAP‐25 and synaptotagmin‐1 (SYT1) were quantified using an immunoprecipitation mass spectrometry method. Linear models were applied to evaluate group differences in CSF biomarker concentrations, adjusting by age and sex. Voxel‐wise linear regressions were also implemented, using VoxelStats, to examine the association between CSF‐ and imaging‐based measures. Result Comparison between groups showed increased concentrations of the CSF biomarkers across disease stages (Figure 1). At the voxel level, consistent associations were found between CSF biomarkers and PET amyloid in AD‐related regions, with the SNAP‐25 biomarkers demonstrating the strongest correlations (Figure 2). Regions with clear associations between tau PET and CSF biomarkers were the inferior temporal, frontal and inferior‐parietal cortices. Again, associated regions were common to all biomarkers, with the strongest correlations found with the SNAP‐25 biomarkers (Figure 3). CSF biomarkers also correlated with GM, but not WM, VBM, being the associated areas in regions commonly affected by AD pathophysiology (Figure 4). Further analyses with SV2A PET should corroborate current findings. Conclusion These results suggest that CSF SNAP‐25 reflects synaptic degeneration and loss in cortical regions affected by amyloid and tau pathology throughout the continuum.